Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose -

-Gemini durably normalizes cellular inflammation and restores immunocompetence -

SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease (CKD) patients peripheral blood mononuclear cells. Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide, a toll-like receptor 4 agonist, in development for the treatment of acute and chronic inflammation-driven diseases such as acute kidney injury (AKI) and CKD.

In the PRIME study, a majority of patients (>85%) had at least one elevated cytokine predose and (>60%) of these patients had elevated inflammatory cytokines IL-1b and IL-6. Treatment with Gemini significantly reduced the number of elevated cytokines at all measured timepoints post-dose out to 7 days (p<0.01 at 2 hours, p<0.02 at 24 hours, and p<0.03 at168 hours) following a single dose of Gemini verses no significant change in placebo. In addition, a majority (>60%) of patients were also found to be non-responsive to stimulation (immunoparalysis) predose. Gemini significantly restored normal responsiveness to LPS stimulation (p<0.02 at 24 hours, p<0.03 at 168 hours) and trended (p=0.06) to improved responsiveness to HMGB1. No significant responses were observed for placebo.

Acute and chronic inflammatory disease is driven by increased cytokine production, as a result of activation of innate immune cells. This dysregulation in cellular activity contributes to perpetuation and progression of disease. Data from the PRIME clinical study demonstrate that treatment with a single dose of Gemini can durably normalize inflammation at the cellular level, and restored immunocompetence.